IN8bio (INAB) H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference summary

Pipeline and clinical progress

• INB-200 is in phase I for GBM, showing promising relapse-free survival in small cohorts, with some patients exceeding 36 months without relapse.

• INB-400, a phase II multicenter study for GBM, has begun enrolling and dosing patients, aiming to validate and expand on INB-200 results with both autologous and allogeneic arms.

• INB-100, in phase I for leukemia, demonstrated 100% morphologic complete response for over 12 months in high-risk patients, with no observed cytokine release syndrome or neurotoxicity.

• Plans are underway for a registrational phase II trial for INB-100, with further design details and IND filing expected later this year.

• Off-the-shelf iPSC-derived gamma delta T cells and a non-signaling CAR T platform are in development, targeting both hematologic and solid tumors.

Gamma delta T cell platform and differentiation

• Gamma delta T cells bridge innate and adaptive immunity, offering direct killing, long-term persistence, and broad target recognition.

• Unlike NK cells, gamma delta T cells persist in the body and are not MHC-restricted, enabling them to target heterogeneous tumor populations.

• The platform aims to achieve durable remissions and reduce relapse by targeting multiple tumor antigens simultaneously.

• Non-signaling CARs for gamma delta T cells are designed to distinguish between healthy and tumor cells, widening the therapeutic index.

• Dual-targeting CARs (CD33 and CD123) have shown increased killing of leukemic cells without harming healthy bone marrow in preclinical studies.

Data highlights and future outlook

• INB-200 data show dose response and long-term remission in GBM, with some patients doubling expected progression-free survival.

• INB-100 patients, despite poor prognostic factors, remain in remission up to 3-4 years, outperforming historical relapse rates.

• No severe adverse events such as cytokine release syndrome or neurotoxicity have been observed in INB-100.

• Upcoming catalysts include phase II trial updates for INB-400, new data releases for INB-200 and INB-100, and IND filings for registrational and allogeneic programs.

• Additional patient enrollment and longer-term follow-up data are expected to be presented at major medical meetings later this year.